Moderna’s experimental mRNA cancer treatment progresses, shares spike
Moderna shares surged after the company announced positive initial results for an experimental mRNA cancer vaccine used in combination with Merck's Keytruda. The treatment showed promise in extending the time melanoma patients lived without cancer returning.
Why it matters
This represents a significant potential breakthrough in personalized cancer immunotherapy, impacting both medical science and biotech market valuations.
Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators.
Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors. In current studies, they are pairing it with Keytruda, a immunotherapy drug made by Merck.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in